H ypoplastic left heart syndrome and other single ventricle congenital heart diseases characterized by severe underdevelopment of the left ventricle result in a single functional pumping chamber of right ventricular morphology. The single right ventricle in these patients must function in relation to the increased afterload of the systemic circulation. As a result, heart failure can result in death or the need for heart transplantation in children with single ventricle congenital heart disease. 1, 2 However, the exact mechanisms underlying heart failure in single ventricle congenital heart disease are poorly understood, limiting the ability to identify effective medical therapies.
Cardiac fibrosis is associated with the progression of heart failure in adults, and the severity of fibrosis is associated independently with cardiovascular mortality. 3, 4 Diffuse, reactive fibrosis of the left ventricle is present by histopathologic evaluation in the majority of explanted hearts from adults with end-stage heart failure. 5 Chronic activation of the renin-angiotensin-aldosterone system (RAAS) in adult heart failure is one mechanism contributing to pathologic cardiac fibrosis. Increased angiotensin II and aldosterone promote the maladaptive accumulation of ACEi Angiotensin-converting enzyme inhibitor Col Collagen ECM Extracellular matrix Gal3
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Transforming growth factor beta TIMPs Tissue inhibitors of metalloproteinases extracellular matrix (ECM) proteins through an imbalance of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs), in part via elevated transforming growth factor beta (TGF-b) signaling, resulting in increased collagen (Col) synthesis and decreased Col breakdown. This imbalance in ECM homeostasis is a hallmark of myocardial fibrosis, and its physiological consequences include increased mechanical stiffness, decreased compliance, and ultimately contractile dysfunction. 3, 4, [6] [7] [8] [9] [10] Pharmacological therapies targeting multiple components of the RAAS pathway have significantly decreased morbidity and mortality in adult patients with left ventricular heart failure; aldosterone antagonists, for example, are used in the setting of RAAS activation to minimize adverse cardiac remodeling including progression of fibrosis. [11] [12] [13] [14] However, activation of the RAAS pathway has not been demonstrated specifically in pediatric patients with single ventricle congenital heart disease, and a double-blind, placebo-controlled trial of the physiology of the angiotensin-converting enzyme inhibitor (ACEi) enalapril in infants with single ventricle congenital heart disease demonstrated that enalapril did not prevent the development of ventricular dysfunction or heart failure. 15 The purpose of this study was to profile fibrosis-related gene expression and histologic fibrosis in the myocardium of pediatric patients with single ventricle congenital heart disease and right ventricular failure.
Methods
Explanted myocardium from children (10 years of age or younger) of all races, sex, and ethnic backgrounds were available for this study through the Institutional Review Boardapproved University of Colorado Pediatric Cardiac Tissue Bank. All heart tissue was dissected and rapidly flash frozen in the operating room immediately after removal from the subject. Subjects with single ventricle congenital heart disease were defined as those patients with ductal-dependent single ventricle physiology. Only those patients with a systemic right ventricle and a hypoplastic left ventricle (n = 19) were included; subjects with single ventricle congenital heart disease of left ventricle morphology were excluded. All hearts with single ventricle congenital heart disease were obtained from patients at the time of transplant. Patients with single ventricle congenital heart disease were divided into 3 groups: the nonfailing single ventricle congenital heart disease group included infants listed for primary transplant without evidence of right ventricular systolic dysfunction on echocardiography, the failing single ventricle congenital heart disease group included infants either without any prior surgical intervention or infants status post stage I surgical palliation with decreased right ventricular systolic function on echocardiogram and right ventricular failure as the main indication for transplantation, and the stage III group, which included children with end-stage Fontan failure (right ventricular failure and/or plastic bronchitis or proteinlosing enteropathy). Nonfailing right ventricular heart disease (n = 8) myocardium was obtained from biventricular hearts without congenital heart disease, acquired from donor children whose hearts could not be placed for technical reasons. To evaluate subjects of similar age and right ventricular volume loading, the failing single ventricle congenital heart disease group was compared with the nonfailing single ventricle congenital heart disease group (both primarily composed of infants) and the stage III group was compared with the nonfailing right ventricular heart disease group.
At the time of explantation, the basal aspect of the ventricles is sent to the clinical pathology laboratory at the Children's Hospital Colorado for routine examination. Hematoxylin and eosin staining was performed on all samples from hearts with single ventricle congenital heart disease and trichrome staining was performed on select specimens at the discretion of the clinical pathologist. For the purposes of this study, a single pediatric pathologist reviewed all available slides. Qualitative assessment of fibrosis was descriptive, noting the presence or absence of fibrosis as well as location, consistent with routine clinical pathologic evaluation.
Total RNA from each frozen tissue sample was extracted using MirVanaRNA Isolation Kit (Ambion #AM1561; Invitrogen, Waltham, MA) as previously described. 16 Reverse transcription of messenger RNA (mRNA) was performed using the iScript cDNA Synthesis Kit (BioRad, Hercules, CA), and reverse transcription of microRNA was performed using the miScript Reverse Transcription Kit (Qiagen, Hilden, Germany) as described. 16 Relative expression of each gene target was quantified using real-time polymerase chain reaction. The mRNA levels of 18S were used for normalization of all mRNA targets, and hsa-miR-361 was used as an internal control for microRNA. 16 The average of at least 2 technical replicates was used for each independent experiment; primer sequences are listed in Table I (available at www.jpeds.com).
All statistical procedures were performed with GraphPad Prism software (GraphPad Software, Inc, La Jolla, CA). MannWhitney tests were performed to compare nonparametric realtime polymerase chain reaction data between the 2 groups. Statistical significance was set a priori at P < .05 and all data are presented as mean ± standard error of the mean. Linear regression was performed to evaluate correlation between continuous variables.
Results
Demographic information for those with single ventricle congenital heart disease, indication for transplantation, medications, and histology results are included in Table II . The nonfailing single ventricle congenital heart disease group had 7 subjects with a median age of 0.19 years (range, 0.05-0.38) and was 86% male. The failing single ventricle congenital heart disease group had 6 subjects with a median age of 0.66 years (range, 0.41-1.27) and was 67% male. The nonfailing right ventricular heart disease group had 8 subjects with a median age of 7.2 years (range, 1.3-9.5) and was 63% male. The stage III group had 6 subjects with a median age of 5.5 years (range, 3.3-10.1) and was 83% male. Six of the subjects with nonfailing single ventricle congenital heart disease (86%), 3 of the subjects with failing single ventricle congenital heart disease (50%), Volume 191 • December 2017 and 3 subjects in the stage III group (50%) were on ACEi therapy. Representative histologic sections of single ventricle congenital heart disease myocardium are illustrated in Figure 1 (available at www.jpeds.com), demonstrating the variability with which fibrosis is detected in this population. The presence of right ventricular fibrosis by histology in young subjects with single ventricle congenital heart disease is inconsistent and is not more prevalent in subjects with single ventricle congenital heart disease with end-stage right ventricular failure: 3 of 8 subjects (38%) with normal right ventricular function had evidence of right ventricular fibrosis, whereas only 2 of 11 subjects (18%) with right ventricular failure had histologic evidence of right ventricular fibrosis (Figure 1) .
Col gene expression, association with age, and expression of myocardial microRNA 29b (miR-29b, a regulator of Col levels) in single ventricle congenital heart disease are shown in Figure 2 . Both Col1a and Col3 are higher in the nonfailing single ventricle congenital heart disease group in comparison with the failing single ventricle congenital heart disease group (Figure 2 , A and B; P = .019 and P = .035, respectively). There is a trend toward an increase in the ratio of Col1a/ Col3 in subjects with nonfailing single ventricle congenital heart disease compared with subjects with failing single ventricle congenital heart disease (Figure 2, C; P = .051); however, this trend did not attain statistical significance. Myocardial miR-29b is upregulated in subjects with failing single ventricle congenital heart disease in comparison with subjects with nonfailing single ventricle congenital heart disease (Figure 2, D; P = .014). Col expression, including Col1a/Col3, and miR-29b expression are similar between subjects with single ventricle congenital heart disease stage III and subjects with nonfailing right ventricular heart disease ( All subjects with single ventricle congenital heart disease are listed, including age at heart explant, sex, most recent surgical intervention before explant, time from last surgical palliation, indication for heart transplantation, and medications at the time of explant. Right ventricular fibrosis type for each subject is listed, obtained from histologic evaluation of the explanted myocardium by clinical pediatric pathologists.
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Expression of other genes involved in ECM regulation are shown in Figure 3 . MMP-2 expression is similar between subjects with nonfailing single ventricle congenital heart disease and subjects with failing single ventricle congenital heart disease (Figure 3, A; P = .37), and there is a trend toward increased MMP-9 expression in the failing single ventricle congenital heart disease group (Figure 3, B ; P = .07). TGF-b1 and TGF-b2 expression is similar between the nonfailing single ventricle congenital heart disease and failing single ventricle congenital heart Col gene expression profile in hearts with single ventricle congenital heart disease. A, Col1a gene expression is lower in the single ventricle congenital heart disease with failure group compared with the single ventricle congenital heart disease with nonfailure group (P = .019). B, Col3 gene expression is lower in the single ventricle congenital heart disease with failure group compared with the single ventricle congenital heart disease with nonfailure group (P = .035). C, Col1a/Col3 ratio is similar between the single ventricle congenital heart disease with failure group and the single ventricle congenital heart disease with nonfailure group (P = .051). D, Myocardial miR-29b is higher in the single ventricle congenital heart disease with failure group compared with the single ventricle congenital heart disease with nonfailure group (P = .014). E-G, Col1a, Col3, and Col1a/ Col3 are similar between stage III and a nonfailing right ventricular heart disease (P = .41, P = .85, P > .99, respectively). H, Myocardial miR-29b is similar between stage III and nonfailing right ventricular heart disease (P = .41). I, Linear regression of Col1a versus age in a subject with nonfailing single ventricular congenital heart disease and a subject with single ventricular congenital heart disease with failure demonstrates a moderate inverse correlation (R 2 = 0.54, P = .004). J, Linear regression of Col3 versus age in subjects with nonfailing single ventricular congenital heart disease and subjects with single ventricular congenital heart disease with failure demonstrates a mild inverse correlation (R 2 = 0.34, P = .036). K, Linear regression of Col1a/ Col3 ratio versus age in subjects with nonfailing single ventricular congenital heart disease and subjects with single ventricular congenital heart disease with failure does not demonstrate a significant correlation (R 2 = 0.22, P = .11). Gene expression of ECM regulators in myocardium with single ventricle congenital heart disease. A, B, MMP-2 and MMP-9 expression is similar between single ventricle congenital heart disease with failure and nonfailing single ventricle congenital heart disease (P = .37, P = .07, respectively). C, D, TGF-b1 and TGF-b2 expression is similar between failing single ventricle congenital heart disease and nonfailing single ventricle congenital heart disease (P = .95, P = .73, respectively). E, F, MMP-2 and MMP-9 expression is similar between stage III and nonfailing right ventricular disease (P = .85, P = .14, respectively). G, H, TGF-b1 and TGF-b2 expression is similar between stage III and nonfailing right ventricular disease (P = .081, P = .081, respectively). I-L, TIMP-1to TIMP-4 expression is similar between failing single ventricle congenital heart disease and nonfailing single ventricle congenital heart disease (P = .95, P = .95, P = .45, P = .73, respectively). M-P, TIMP-1, TIMP-3, and TIMP-4 are lower in stage III compared with nonfailing right ventricular heart disease (P = .0047, P = .013, P = .013, respectively). TIMP-2 expression is similar between the 2 groups (P = .75).
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Discussion
Our current findings demonstrate that neither histologic fibrosis nor a profibrotic gene expression profile is a consistent hallmark of right ventricular failure in young patients with a single ventricle. Given known developmental upregulation and accumulation of Col during the neonatal period, 18, 19 infant patients with a single ventricle were analyzed separately from the stage III pediatric subjects, which also served to minimize changes that may arise solely from differences in right ventricular volume load. Because the primary emphasis of our analysis was to study fibrosis and changes in fibrotic gene expression in response to right ventricular failure, infants with single ventricle congenital heart disease and associated right ventricular failure (failing single ventricle congenital heart disease group) were compared to infants with a single ventricle and normal right ventricular function who underwent elective heart transplantation (nonfailing single ventricle , and Gal3 expression is similar between failing single ventricle congenital heart disease and nonfailing single ventricle congenital heart disease (P = .53, P > .99, P = .70, respectively). D-F, Myocardial Corin and ST2L expression is similar between stage III and nonfailing right ventricular heart disease (P = .14, P = .14, respectively). Gal3 expression is decreased in stage III compared with nonfailing right ventricular heart disease (P = .043).
congenital heart disease) and pediatric subjects with single ventricle with right ventricular failure after stage III (stage III) were compared with subjects with nonfailing right ventricular heart disease. Results from both infant and young subjects with single ventricle suggest that pathologic right ventricular fibrosis may not be a primary contributor to right ventricular dysfunction in pediatric patients with single ventricle and the putative benefit of antifibrotic agents may be limited in this population. 15, 17, 20 In the predominantly infant-aged cohort that either did not undergo any surgical palliation or underwent stage I palliation, Col expression is significantly lower in subjects who were transplanted for right ventricular failure compared with those subjects with single ventricle who underwent elective heart transplantation. This finding is contrary to the hypothesis that myocardial fibrosis is contributory to right ventricular failure in this population. Moreover, this decreased Col expression in failing single ventricle congenital heart disease may represent adverse remodeling that predisposes to ventricular dilation and dysfunction, akin to the adverse ECM remodeling process acutely after myocardial infarction where failure of ECM support has been associated with ventricular wall thinning and slippage of myocyte fascicles. 21 In addition, the trend toward increased MMP-9 and unchanged TIMP expression may favor ECM degradation and loss of ECM organization in the failing single ventricle congenital heart disease group. Independent of the involvement of MMP-9 in ECM degradation, MMP-9 is known to compromise contractile function of cardiomyocytes through the proteinase-activated recptor-1 signaling cascade, 22 and may contribute to right ventricular dysfunction in failing single ventricle congenital heart disease. Additionally, the miR-29 family targets and downregulates many fibrosis-related mRNAs, including multiple Col types, fibrillins, and elastin. 23 Elevated miR-29b in failing single ventricle congenital heart disease may be consistent with ongoing Col degradation and the general antifibrotic milieu in this group, which is in stark contrast with the downregulation of miR-29 in the region of fibrotic scar after myocardial infarction. 24 A caveat to the argument that the lower Col content in failing single ventricle congenital heart disease is detrimental arises from the significant age difference between the nonfailing single ventricle congenital heart disease and failing single ventricle congenital heart disease groups. Although all subjects in the nonfailing single ventricle congenital heart disease and failing single ventricle congenital heart disease groups were less than 1.5 years of age, subjects in the nonfailing single ventricle congenital heart disease group are younger than those in the failing single ventricle congenital heart disease group (P = .0012). Given the significant inverse correlation between Col1a and Col3 expression and age in this cohort (Figure 2) , higher Col1a and Col3 gene expression in the nonfailing single ventricle congenital heart disease group may be a physiological process that contributes to a developmental accumulation of functional Col, similar to what has been previously described in animal models. 18, 19 Last, an attenuated fibrotic response has been demonstrated specifically in young rats 25 and in pediatric patients with dilated cardiomyopathy, 26 suggesting that age and duration of disease also influence fibrosis development. Although we cannot determine whether Col downregulation is pathologic in single ventricle congenital heart disease based on our current associative data, our results do support the conclusion that right ventricular failure can occur independently from histologic fibrosis and profibrotic gene expression, the latter of which also varies with age in young patients with single ventricle congenital heart disease. With regard to patients with single ventricle who required heart transplant after stage III surgical palliation, there is also absence of a profibrotic Col expression profile. In particular, prior studies have demonstrated that an elevated Col1a/ Col3 ratio is associated with a detrimental increase in myocardial stiffness, decreased ejection fraction, and increase left ventricular end-diastolic pressure. [27] [28] [29] [30] Interestingly, in our single ventricle congenital heart disease cohort, there is a trend toward increased Col1a/Col3 ratio in subjects with histologic evidence of right ventricular fibrosis, illustrating the association between gene expression and the histologic presence of fibrosis (P = .084, Figure 5 ; available at www.jpeds.com). Notably, the Col1a/Col3 ratio in stage III subjects was equivalent to the nonfailing right ventricular heart disease group. Additionally, Gal3, a soluble beta-galactoside-binding lectin released by activated cardiac macrophages has been shown to induce cardiac fibroblast proliferation, Col deposition, and ventricular dysfunction in animal models, 31 with inhibition of Gal3 resulting in attenuated cardiac fibrosis. 32 Low Gal3 expression in stage III when compared with nonfailing right ventricular heart disease supports a possible downregulation of Gal3-related fibrotic pathways.
A striking difference between stage III and nonfailing right ventricular heart disease emerges when evaluating TIMP expression: TIMP-1, TIMP-3, and TIMP-4 are markedly downregulated in the stage III group. Interestingly, the downregulation of TIMP-1, TIMP-3, and TIMP-4 in stage III is similar to what has previously been described in ischemic cardiomyopathy 33 as well as adult idiopathic dilated cardiomyopathy, 26 although increases in TIMP-1 to TIMP-4 have also been described in adult dilated cardiomyopathy. 29 TIMPs are potent reversible inhibitors of activated MMPs and may have additional MMP-independent profibrotic activity. 34 Alterations in TIMP expression seem to be variable among disease etiologies and heart failure stages, 34 suggesting that the regulation of TIMPs are not solely determined by MMP levels, even though an interplay between MMPs and TIMPs is required to maintain ECM homeostasis. It is postulated that this low expression of TIMPs in stage III would favor ECM degradation and turnover. Alternatively, this pattern of TIMP downregulation may represent a common, end-stage phenotype.
Assessment of TGF-b1 and TGF-b2 expression did not demonstrate any differences between subjects with stage III disease and those with nonfailing right ventricular heart disease. Both TGF-b1 and TGF-b2 are profibrotic, 35, 36 with trends toward increased TGF-b expression in adult dilated cardiomyopathy. 30 Given the known upregulation of TGF-b1 by angiotensin II, 37 it is worth noting that 50% of the subjects with stage III were THE JOURNAL OF PEDIATRICS • www.jpeds.com Volume 191 on ACEi at the time of explant; however, among our small cohort of subjects with stage III (n = 6), TGF-b1 expression was similar between those with and without ACEi treatment (P > .99). The role of TGF-b2 in cardiac fibrosis is not welldefined, although in a model of hypertrophic cardiomyopathy there is suggestion that a decrease in myocardial TGF-b2 is associated with less fibrosis. 36 The trend toward increased TGF-b2 in stage III could represent a propensity for fibrosis; however, this is a difficult conclusion to make, particularly in the context of equivocal or antifibrotic regulation of other fibrosis-related genes. Certainly, TGF-bs are involved in a wide variety of cell functions aside from promoting ECM deposition.
The current study has several limitations. First, histologic results were obtained from routine clinical pathologic evaluation of the explanted myocardium by hematoxylin and eosin, and occasional trichrome staining; thus, it is possible that a more specific histologic evaluation of the myocardium could reveal a higher incidence of right ventricular fibrosis. However, the minimal histologic evidence of fibrosis in single ventricle congenital heart disease is consistent with the lack of upregulation of fibrosis-related gene expression in the single ventricle congenital heart disease myocardium. Second, gene expression assessment of MMPs and TIMPs at the mRNA level may not completely reflect their physiologic level of activity. Although all failing single ventricle congenital heart disease samples are considered to have end-stage right ventricular failure, assessment of MMP and TIMP levels at 1 point in time may not necessarily reflect the dynamic nature of this proteolytic system. 21 Nevertheless, alterations in fibrosis-related genes are present before overt phenotypic changes 38 ; thus, the lack of a prominent fibrotic gene expression pattern may suggest that, excluding new cardiovascular insults, future fibrosis would be minimal. Third, in this study we chose to investigate select genes of interest implicated in promoting fibrosis in humans and animal models of heart failure. 29, [39] [40] [41] [42] There are likely other mechanisms contributing to right ventricular dysfunction in single ventricle congenital heart disease that were not evaluated, such as enhanced myocardial Col cross-linking 43 or increased myofibril-mediated stiffness via titin hypophosphorylation. 28 Fourth, it is important to recognize that the single ventricle congenital heart disease explants in our cohort are infants and children with a maximum age of 10 years (with only 3 patients older than 5 years). There is a population of older patients with single ventricle congenital heart disease who experience right ventricular failure as adolescents and young adults and, given the significant influence of age, it is unlikely that our results are translatable to an older single ventricle congenital heart disease heart failure population. Fifth, as noted, it is possible that the use of ACEi (86% of nonfailing single ventricle congenital heart disease, 60% of failing single ventricle congenital heart disease, 50% of stage III) may have decreased fibrosis development. Further statistical investigations were limited secondary to the relatively small sample size; however, 80% of subjects with single ventricle congenital heart disease with histologic evidence of fibrosis were on ACEi therapy. Importantly, possible prevention of fibrosis with ACEi did not preclude the development of right ventricular failure. Finally, our cohort is small, which is a limitation inherent to single-center studies in the single ventricle congenital heart disease population and makes it challenging to draw definitive conclusions based on statistical significance.
In conclusion, fibrosis is not a primary contributor to right ventricular failure in infants and young children with single ventricle congenital heart disease. This attenuated fibrotic response may be secondary to young age and short duration of disease (characteristic of this disease process) and possibly differences between right ventricular and left ventricular adaptation. Thus, pharmacologic interventions targeting the development of fibrosis may have limited benefit and require additional investigations specifically in the young single ventricle congenital heart disease population. ■ Histologic evaluation of myocardium with single ventricle congenital heart disease. A, Hematoxylin and eosin (H&E) stained section of right ventricular myocardium from a subject with single ventricle congenital heart disease with failure demonstrating normal myocardium without significant fibrosis. Scale bar equals 200 µm. B, H&E-stained section of right ventricular myocardium from a subject with single ventricle congenital heart disease with failure with mild, diffuse interstitial fibrosis. Scale bar equals 500 µm. C, Trichrome-stained section of right ventricular myocardium from a subject with single ventricle congenital heart disease with failure with both interstitial fibrosis and subendocardial fibrosis. Scale bar equals 500 µm. D, Prevalence of right ventricular fibrosis is low (3/8, 38%) by histology in this cohort of subjects with single ventricle congenital heart disease with normal right ventricular systolic function. E, Right ventricular fibrosis occurs in a minority of subjects with single ventricle congenital heart disease (2/11, 18%) with end-stage right ventricular failure.
Table I. Primer Sequences for real-time polymerase chain reaction

Primer Sequence
Corin F GCT GGC AGG AGA TAT TGA GTC Corin R TGT AAA GTG GTC CCA TTG AGG Gal-3 F GAG CCA GCC AAC GAG CGG AA Gal-3 R  CTT GAG GGT TTG GGT TTC CAG A  ST2L F  CCT ACC ATT GAC CTC TAC AAC TG  ST2L R  TAA TCA CCT GCG TCC TCA G  TGF-b1 F  GCC TTT CCT GCT TCT CAT GG  TGF-b1 R  TCC TTG CGG AAG TCA ATG TAC  TGF-b2 F  CCA AAG GGT ACA ATG CCA AC  TGF-b2 R  TCT AAA TCT TGG GAC ACG CAG  TIMP-1 F  GGT CCCAGA TAG CCT GAA TC  TIMP-1 R  GAA AGA TGG GAG TGG GAA CAG  TIMP-2 F  CCC TCT GTGACT TCA TGG TG  TIMP-2 R  GAG ATG TAG CAC GGG ATC ATG  TIMP-3 F  CCT TCT GCA ACT CCG ACA TC  TIMP-3 R  GCC TCG GTA CAT CTT CAT CTG  TIMP-4 F  CTA CCA TCT GAA CTG TGG CTG  TIMP-4 R  CTA CCA TCT GAA CTG TGG CTG  MMP-2 F  GAC GAT GAG CTA TGG ACC TTG  MMP-2 R  GTT GTA CTC CTT GCC ATT GAA  MMP-9 F  CTG GAG GTT CGA CGT GAA G  MMP-9 R  TCC TGG CAG AAA TAG GCT TTC  miR-29b  GGG TAG CAC CAT TTG AAA TCA GTG TT  Col1a F  CCCTGGAAAGAATGGAGATG  Col1a R  TCCAAACCACTGAAACCTCTG  Col3 F  AAG TCA AGG AGA AAG TGG TGG  Col3 R  CTC GTT CTC CAT TCT TAC GAC G  U6  CGG CAG CAC ATA TAC TAA AAT  18S F  GCC GCT AGA GGT ATT CTT G  18S R  CTT TCG CTC TGG TCC GTC GTC TT Listed are the forward (F) and reverse (R) primer sequences used for each target gene. All primers are presented in a 5′-3′ orientation.
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Fibrosis-Related Gene Expression in Single Ventricle Heart Disease Figure 5 . Single ventricle congenital heart disease fibrosis-related gene expression grouped by presence of histologic fibrosis. There is no difference in myocardial expression in single ventricle congenital heart disease of any of the gene targets. There is a trend toward increased Col1a/Col3 in hearts with single ventricle congenital heart disease, with histologic evidence of right ventricular fibrosis (P = .084).
